News related to Paclitaxel and/or conditions it is approved for
Paclitaxel Plus Chemo Improves Outcomes in Early Breast Cancer
Source: MedicineNet cyclophosphamide Specialty [2008.05.28]
Title: Paclitaxel Plus Chemo Improves Outcomes in Early Breast Cancer
Category: Health News
Created: 5/28/2008 2:00:00 AM
Last Editorial Review: 5/28/2008
Gemcitabine Plus Paclitaxel Increases Survival in Metastatic Breast Cancer
Source: Medscape Pharmacotherapy Headlines [2004.06.10]
Time to progression is also significantly better than with paclitaxel alone, and the combination does not increase toxicity.
Medscape Medical News
Amgen, Takeda And Millennium Provide Update On Phase 3 Trial Of Motesanib In Patients With Non Small Cell Lung Cancer
Source: Lung Cancer News From Medical News Today [2008.11.21]
Amgen (Nasdaq: AMGN) and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4052), announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC).
Study First To Combine 2 Chemotherapies And 2 Targeted Therapies
Source: Lung Cancer News From Medical News Today [2008.11.14]
The four drug-combination of carboplatin and paclitaxel, with the targeted therapies bevacizumab (Avastin) and cetuximab (Erbitux), is safe and may improve survival for patients with advanced lung cancer, according to a cooperative group study led by The University of Texas M. D. Anderson Cancer Center.
|
